"We are delighted to report this highly encouraging progression-free survival data in Met-driven papillary renal cell carcinoma (PRCC), a disease with no approved treatment options," said Christian Hogg, CEO of Hutchison China MediTech Ltd. (Chi-Med). "With development of the companion diagnostic assay to screen Met-driven disease now also complete we are preparing for the initiation of our global Phase III study, the first global registration trial for savolitinib."
[Sidebar#SC097066]






